Thus, multiple studies have examined the efficacy of combining MEK inhibitors with PI3K/AKT/mTOR [25, 47], Bcl-xL [26], CDK4/6 [27, 28], or autophagy [29–31] inhibitors in preclinical models of various tumors, including CRC. The gene discussed is BCL2L1; the disease is colorectal carcinoma.